Search clinical trials for: Open label study

Total 124857 results

Wuhan Union Hospital, China
Renmin Hospital of Wuhan University

Recruiting

Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study

Locally Advanced Rectal Cancer

China
Rousselot BVBA

Not yet recruiting

An Open Label, Dose-escalation Study, Assessing the Safety and Tolerability of a Collagen Peptide

Tolerance

United States
Tenaya Therapeutics
Johns Hopkins University; Mayo Clinic

Recruiting

Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC (RIDGE-1)

Arrhythmogenic Right Ventricular Cardiomyopathy

United States
Shanghai Yuyao Biotech Co., Ltd.

Recruiting

An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies

Advanced Solid Tumor | Hematological Malignancy

China
Nanfang Hospital, Southern Medical University

Recruiting

A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL (ABC)

Acute Lymphoblastic Leukemia | Philadelphia Chromosome | Adult ALL | Philadelphia-Positive ALL | IKZF1 Gene Mutation

China
Ardelyx

Recruiting

An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females

Lactation

United States
Azure Biotech Inc.

Not yet recruiting

Open-Label Study of Vaginal AZU-101 in Postmenopausal Women

Postmenopausal Symptoms
Proviva Therapeutics, Inc.

Not yet recruiting

A First-in-human (FIH), Multicenter, Open-Label, Phase I Study of PTX-912 in Patients With Locally Advanced/Metastatic Solid Tumors

Solid Tumor | Metastatic Cancer | Advanced Cancer
Amgen

Recruiting

Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) (N-MOmentum LT)

Neuromyelitis Optica Spectrum Disorder

Korea, Republic of, Thailand, Hong Kong, Hungary, Poland
Viridian Therapeutics, Inc.

Recruiting

An Open-label Study for Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies (OLE)

Thyroid Eye Disease

United States, Spain
Zai Lab (Shanghai) Co., Ltd.
Zai Lab (US) LLC

Recruiting

An Open-label, Multicenter Study of ZL-1310 in Subjects With Small Cell Lung Cancer

SCLC

United States, China
PharmAust Ltd
Macquarie University, Australia; Calvary Health Care Bethlehem

Recruiting

An Open Label Extension Study of Monepantel in Individuals With Motor Neurone Disease

Motor Neuron Disease

Australia
Spirair, Inc

Recruiting

Open-Label Study to Evaluate the Safety and Effectiveness of the Spirair Implant

Nasal Airway Obstruction | Nasal Septal Deviation

United States
Apellis Pharmaceuticals, Inc.

Recruiting

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Geographic Atrophy

United States
Cabaletta Bio

Recruiting

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy

Idiopathic Inflammatory Myopathy | Dermatomyositis | Immune-Mediated Necrotizing Myopathy | Anti-Synthetase Syndrome

United States
Vectorious Medical Technologies Ltd.

Not yet recruiting

A Multi-center, National, Open-label, Prospective Study to Evaluate the Performance of the V-Lap™ System

Heart Failure
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma

Liver Carcinoma | Hepatic Cell Carcinoma

China
Ki Health Partners. LLC
Revance Therapeutics, Inc.; The Los Angeles Headache Center

Recruiting

Open Label, 6-month Study for High Frequency and Chronic Migraine,

Chronic Migraine, Headache

United States
Chinese University of Hong Kong

Recruiting

Open-label Pilot Study Synbiotic Treatment for Autism Spectrum Disorder

Anxiety | Autism Spectrum Disorder

Hong Kong
Liquidia Technologies, Inc.

Recruiting

An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH (ASCENT)

Pulmonary Hypertension | Interstitial Lung Disease

United States
Duke University

Not yet recruiting

Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252 (PuMP)

Recurrent High Grade Glioma
Gamaleya Research Institute of Epidemiology and...

Not yet recruiting

An Open-label Study of the Safety and Pharmacokinetics of the TGKP

Acute Respiratory Distress Syndrome (ARDS)
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease

Thyroid Eye Disease, TED

China
Cabaletta Bio

Recruiting

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus | Lupus Nephritis

United States
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.

Recruiting

An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM

Obstructive Hypertrophic Cardiomyopathy

China
M.D. Anderson Cancer Center

Recruiting

A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United States
M.D. Anderson Cancer Center
Sanofi US Services, Inc

Recruiting

Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Sanofi
Regeneron Pharmaceuticals

Recruiting

A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)

Eosinophilic Oesophagitis

United States, Canada, Israel
Rocket Pharmaceuticals Inc.

Recruiting

A Multi-Center, Open Label Gene Therapy Study of RP-A501 in Male Patients With Danon Disease

Danon Disease

United States
Cancer Institute and Hospital, Chinese Academy...

Recruiting

A Prospective, Open-label, Multicenter, Randomized Controlled Phase III Study of Prophylactic Central Neck Dissection in Low-risk Papillary Thyroid Cancer

Recurrence | Thyroid Cancer

China
San Diego Sexual Medicine

Not yet recruiting

An Open-Label Study of 50 mg Oral Testosterone Undecanoate (Kyztrex) in Menopausal Women With Low Testosterone and HSDD

Hypoactive Sexual Desire Disorder

United States
Mao Jianhua
Tongji Hospital; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine and other collaborators

Recruiting

Study of Adrenocorticotropic Hormone on Children With Frequent Relapse or Steroid-dependent Nephrotic Syndrome: a Prospective, Multicenter, Randomized，Open-label Clinical Trial.

Nephrotic Syndrome in Children

China
Vivacelle Bio

Not yet recruiting

A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02) (VBI-S-02)

Sepsis | Septic Shock | Hypovolemia
TWi Biotechnology, Inc.

Recruiting

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Generalized Epidermolysis Bullosa Simplex

United States, Taiwan, Australia, Philippines, Austria, Italy, Poland
Hangzhou Sumgen Biotech Co., Ltd.

Recruiting

An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors (CSG-1827-101)

Advanced Solid Tumors

China
Italfarmaco

Recruiting

A Multicentre, Prospective, Open-label, Non-comparative Study

Contraception

Italy
Escient Pharmaceuticals, Inc

Recruiting

Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria (CALM-CIndU)

Chronic Inducible Urticaria

Spain, United States, Germany, Canada, Netherlands
Hoffmann-La Roche

Recruiting

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

Large B-Cell Lymphoma

Belgium, Korea, Republic of, China, Japan, Australia, United States, Italy, Spain, Taiwan, United Kingdom, Germany, France, Canada, Mexico, Poland, Turkey, Switzerland, Brazil, Argentina, Denmark
Novartis Pharmaceuticals

Recruiting

Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.

Chronic Spontaneous Urticaria

Switzerland, Australia, Italy, Spain, France, Germany, Korea, Republic of, Netherlands, Taiwan, India, Czechia, Malaysia, Argentina, Hungary, Thailand, Turkey, Canada, Bulgaria, Slovakia, Brazil, Poland
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd

Recruiting

Open-Label Study to Assess Meplazumab in Adult Patients Diagnosed With Plasmodium Falciparum

Malaria

Kenya
M.D. Anderson Cancer Center

Recruiting

A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Leukemia

United States
CMP Development, LLC

Not yet recruiting

A Phase IV, Two-part, Open-label Study Assessing the Pharmacokinetics, Safety and Pharmacodynamics of Spironolactone Oral Suspension in Pediatric Patients

Edema Due to Heart Failure or Cirrhosis

India
Samsung Medical Center

Not yet recruiting

An Open Label Phase II Study of First-Line Maintenance Enzalutamide Following Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Castration-Naive Prostatic Adenocarcinoma

Prostatic Adenocarcinoma

Korea, Republic of
Tri.O Medical LTD

Recruiting

Proof of Concept Open Label, Clinical Trial to Evaluate the Safety and Efficacy of the "FITT" Device in Diabetic Foot Ulcers Patients (TriO FITT)

Diabetic Foot Ulcer

Israel
FeetMe
University Hospital, Lille

Not yet recruiting

A Randomised, Controlled, Open-Label, Multi-Centre Study to Evaluate the Efficacy of FeetMe® Home-Bases Rehabilitation Program in Comparison to Conventional Physiotherapy in Patients With Parkinson's Disease Using Connected Insoles (Re-Connect)

Parkinson Disease | Gait Disorders, Neurologic
Xencor, Inc.

Recruiting

A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors

Solid Tumors

United States
Joseph C. Wu

Not yet recruiting

Open-Label Dose-Escalation Treatment Study of Patients With IPF (DIAMOND)

Idiopathic Pulmonary Fibrosis

United States
M.D. Anderson Cancer Center
Eli Lilly and Company; BioMed Valley Discoveries, Inc

Recruiting

Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

Metastatic Colorectal Cancer

United States
Novartis Pharmaceuticals

Recruiting

A Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With PSMA-positive Prostate Cancer With or Without Prior 177Lu-PSMA Radioligand Therapy.

Metastatic Castration-resistant Prostate Cancer (mCRPC)

France
Sanofi

Recruiting

A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria

Phenylketonuria

Turkey, United States

3

Subscribe